KPRX
Kiora Pharmaceuticals
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 2
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KPRX
Kiora Pharmaceuticals, Inc.
A clinical-stage biotechnology company that develops the treatments for ophthalmic diseases
332 Encinitas Blvd., Suite 102, Encinitas, CA 92024
--
Kiora Pharmaceuticals, Inc., was incorporated as a Delaware corporation on December 26, 2004 under the name EyeGate Pharmaceuticals, Inc., and changed its name to Kiora Pharmaceuticals, Inc., effective November 8, 2021. The Company is a clinical stage specialty pharmaceutical company focused on the development and commercialization of therapies and drug delivery for the treatment of eye diseases.
Company Financials
EPS
KPRX has released its 2023 Q3 earnings. EPS was reported at -0.89, versus the expected -0.35, missing expectations. The chart below visualizes how KPRX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
